Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00510393
NCT00510393CompletedPhase 2

The DESTINY Trial: a Prospective Randomized Multicenter Trial Comparing the Implant of a Drug Eluting Stent (XIENCE V, Abbott Vascular) vs. a Bare Metal Stent (MULTILINK VISION, Abbott Vascular) in the Critically Ischemic Lower Leg

Flanders Medical Research Program5 sites in 3 countries140 target enrollmentStarted: March 1, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
140
Locations
5
Primary Endpoint
Angiographic patency, defined as angiographic binary in-stent restenosis rate (>50% stenosis).
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The Destiny trial compares the use of bare metal stent systems with drug eluting stent systems in the treatment of infrapopliteal lesions in patients with Critical Limb Ischemia. It will be investigated whether there is a difference in 12 month angiographic patency of the stented area using the 2 different stent systems.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Stenotic (> 50%) or occlusive atherosclerotic disease of the infrapopliteal arteries
  • •A maximum of two focal target lesions in one or more infrapopliteal vessels
  • •Length of lesion is maximally 40 mm, allowing maximally 2 stents to be implanted
  • •Reference vessel diameter should be 2-3.5 mm
  • •Symptomatic critical limb ischemia (Rutherford 4, 5)
  • •The patient must be > 18 years of age
  • •Life-expectancy of more than 12 months
  • •The patient has no child bearing potential or negative serum pregnancy test within 7 days of the index procedure
  • •The patient must be willing and able to return to the appropriate follow-up times for the duration of the study
  • •The patient must provide written patient informed consent that is approved by the ethics committee

Exclusion Criteria

  • •Patient refusing treatment
  • •The reference segment diameter is not suitable for available stent design.
  • •Unsuccessfully treated (>30% residual stenosis) proximal inflow limiting arterial stenosis
  • •Untreatable lesion located at the distal outflow arteries
  • •More than two infrapopliteal lesions in the same limb
  • •Previously implanted stent(s) or PTA at the same lesion site
  • •Lesion location requiring kissing stent procedure
  • •Lesion lies within or adjacent to an aneurysm
  • •Inflow-limiting arterial lesions left untreated
  • •The patient has a known allergy to heparin, Aspirin or other anticoagulant/anti-platelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.
  • •The patient takes Phenprocoumon (Marcumar).
  • •The patient has a history of prior life-threatening contrast media reaction.
  • •The patient is currently enrolled in another investigational device or drug trial.
  • •The patient is currently breast-feeding, pregnant or intends to become pregnant.
  • •The patient is mentally ill or retarded.
  • •Subject has received a heart transplant or any other organ transplant or is on a waiting list for any organ transplant
  • •Subject is receiving or scheduled to receive anticancer therapy for malignancy within 30 days prior to or after the procedure
  • •Subject is receiving immunosuppression therapy, or has known serious immunosuppressive disease (e.g., human immunodeficiency virus), or has severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., systemic lupus erythematosus, etc.) The patient should also not receive inhibitors of CYP3A (such as Itraconazole, and Erythromycin), or inducers of CYP3A (such as Rifampin) within 90 days following the procedure.
  • •Subject is receiving or is scheduled to receive chronic anticoagulation therapy (e.g., heparin, coumadin)
  • •Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure

Arms & Interventions

2

Placebo Comparator

Bare Metal Stent

Intervention: MULTILINK VISION coronary stent system (Device)

1

Experimental

drug eluting stent

Intervention: XIENCE V everolimus eluting coronary stent system (Device)

Outcomes

Primary Outcomes

Angiographic patency, defined as angiographic binary in-stent restenosis rate (>50% stenosis).

Time Frame: one year

Secondary Outcomes

  • Technical success defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30% and residual stenosis less than 50% by duplex ultrasound (US) imaging.(procedure)
  • Primary patency rate at each follow-up. Patients that did not receive any BTK-reintervention and do not exhibit significant restenosis on duplex (PVR ≥ 2.4) are defined as being primary patent at the given follow-up.(one year)
  • Limb-salvage rate (LSR) defined as 1 minus major amputation rate (major amputation is defined as at or above ankle, as opposed to minor amputation being at or below metatarsus preserving functionality of foot).(one year)
  • Clinical events defined as fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization.(one year)
  • Clinical success defined as an improvement of Rutherford classification of one class or more as compared to the pre-procedure Rutherford classification.(one year)

Investigators

Sponsor Class
Network

Study Sites (5)

Loading locations...

Similar Trials

Completed
Not Applicable
Drug Eluting Stent Zilver PTX vs Bare Metal Stent Zilver FlexVascular Diseases
NCT05296031Skane University Hospital49
Completed
Phase 4
Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft LesionsArteriosclerosis of Arterial Coronary Artery Bypass Graft
NCT00611910Deutsches Herzzentrum Muenchen610
Completed
Not Applicable
Evaluating the Safety and Efficacy of the Maurora® DES in ICASStroke (CVA) or TIAIntracranial Arteriosclerosis
NCT05719883Beijing Tiantan Hospital156
Terminated
Phase 4
Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation)Coronary Artery Disease
NCT00440674Conor Medsystems18
Recruiting
Not Applicable
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease TrialICAD - Intracranial Atherosclerotic DiseaseICAS - Intracranial AtherosclerosisDrug-eluting StentDrug Eluting Stents (DES)Medical TreatmentStroke
NCT04948749Beijing Tiantan Hospital358